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ABSTRACT
Abou Issa, Abdelfatah. M.S., Department of Pharmacology and Toxicology, Wright State
University, 2016. Effect of Oasis-ultra Matrix on the Healing Rate of Stage IV Pressure Wounds.

Introduction: (Oasis-ultra) is an extra cellular collagen rich matrix derived from porcine
intestinal sub-mucosa. A prospective, multi-centered, randomized, single-blinded clinical
trial was conducted to study the effects of Oasis-ultra combined with negative pressure
wound therapy (NPWT) on the healing rate of stage IV pressure wounds versus NPWT
alone.
Materials and Methods: Twelve subjects were involved in the study: six patients in the
study group and six in the control group. NPWT was changed twice a week for all subjects,
and Oasis-ultra was applied weekly. The wounds were measured weekly, and the healing
rate was calculated for each subject for 12 weeks. The canisters were collected monthly for
three months. For cytokine and growth factors analysis, 100 µl 1XPBS were added to the
sample, and protein concentration was determined using the Bradford assay. A Bio-Rad
BioPlex 96 well plate was set up with 50 µl of the sample and duplicated for cytokine
analysis using Bio-Plex.
Results: In the study group, the healing rate calculated at 12 weeks was found to be ~87%
when compared to the control group, which was ~55%. Analysis of different growth
factors, normally present in stage IV pressure wounds, revealed higher concentrations in
the oasis-ultra treated group when compared with the control group. Additionally, the other
proinflammatory cytokines that accused of wound chronicity were down regulated as a
result of treating the subjects in the study group with oasis-ultra.
Conclusion: Our study demonstrates that the use of Oasis-ultra accelerates the healing rate
of stage IV pressure wounds when combined with NPWT. Also, in the Oasis-ultra treated
group, the proinflammatory cytokines were successfully inhibited. At the same time, Oasis-
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ultra promoted and upregulated the beneficial growth factors that had positive impact on the
healing rate.
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Introduction:
Skin is the largest organ in the body. It works as a protective layer against toxins
and microorganisms, and provides chemical protection against invasion by toxins and
microorganisms. Also, skin plays an important role in thermoregulation and prevention of
dehydration. (Choi, Uyama, Lee, & Sung, 2015) A wound can be defined as a breakdown
in the protective function of the skin. Also, wounds can be defined as disruption in the
epithelial lining of the skin or mucosa due to either physical or thermal injury (Dhivya,
Padma, & Santhini, 2015; Lazarus et al., 1994).
A better understanding of wound healing is essential to help reducing patient
morbidity and mortality related to abnormal or prolonged wound healing. Wound healing
is a dynamic and complex process occurring in response to tissue injury, which is
accomplished through four highly integrated, matriculated and overlapping phases:
hemostasis or coagulation, inflammation, proliferation, and remodeling or maturation.
(Dhivya et al., 2015; Guo & Dipietro, 2010; Rosique, Rosique, & Farina Junior, 2015)
Wound healing phases are affected by active biological substances either directly or
indirectly, like growth factors and cytokines. Also, other factors affecting wounds (Guo &
Dipietro, 2010) which are classified into local factors and systemic factors. The local
factors include, oxygen supply which is very critical for proliferation, angiogenesis and
collagen production (Schreml et al., 2010; Zhong, 2011), infection, foreign body, venous
sufficiency. The systemic factors include, age, gender, sex hormones, stress, ischemia,
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diabetes, obesity, medications, like glucocorticoid, non-steroidal anti-inflammatory
medications, chemotherapy, alcohol and smoking, nutrition, immune-compromised
conditions, such as cancer, radiation therapy, AIDS (Dhivya et al., 2015; Guo & Dipietro,
2010).
In general, acute wounds heal within 2–4 weeks, (Schreml et al., 2010; Zhong,
2011) while chronic wounds show failure of healing within 12 weeks despite treatment, or
delayed-healing which can extend up to 48 weeks without treatment (Guo & Dipietro,
2010). Nowadays, the concept of an ‘‘ideal dressing’’ should not only provide appropriate
moisture and protective role to the wounds, nevertheless, should also directly stimulate
cellular proliferation, differentiation and migration. Researchers for 3 previous decades,
focused on cellular growth factors and opportunities of their use in the treatment of chronic
wounds. (Stanirowski, Wnuk, Cendrowski, & Sawicki, 2015)

Chronic wounds:

Chronic wounds affect millions of Americans and cost the country annually around
$50 billion (Brem, Kirsner, & Falanga, 2004; L. Shi & Ronfard, 2013). Also, around 35
million cutaneous wounds require major intervention every year (Shapira et al., 2015;
Tonnesen, Feng, & Clark, 2000). In the U.S. alone, chronic wounds not only consume a
great deal of healthcare resources all over the world, but they are really a big challenge to
wound-care professionals as well. Different underlying pathologies make different types
of chronic wounds difficult to heal. From the literature, many research articles mentioned
the high prevalence of people who complain of chronic wounds. Here is some factors that
are mentioned in previous research articles associated with chronic wounds like, age
2

(Gosain & DiPietro, 2004), smoking (Goldminz & Bennett, 1991), obesity and other
comorbid diseases, such as diabetes, venous and arterial insufficiency (Gainza, Villullas,
Pedraz, Hernandez, & Igartua, 2015; Menke, Ward, Witten, Bonchev, & Diegelmann,
2007). The most abundant inflammatory cells in chronic wounds are neutrophils which are
accused of releasing large amounts of proteases. As a result, with more inflammation,
wounds will remain in the inflammatory phase with failure to progress to proliferative
phase. Therefore, the best way for better understanding of the differences between various
types of chronic wounds, we should have a deep background understanding of wound
phases and the molecular and cellular biology that happens in order to improve our
treatment approaches, leading to better healing rates, and facilitating the development of
new effective therapies, which leads to better clinical outcome (Frykberg & Banks, 2015).
Chronic, non-healing wounds could occur as a complication of different disorders related
to lack of oxygen and nutrients which are necessary to the wound cells proliferation and
migration (Guo & Dipietro, 2010). As a result, chronicity makes wounds a potential source
of infection and ends by necrosis of the surrounding tissues and makes healing hard to
obtain (Stanirowski et al., 2015). Reassessment of underlying pathology and consideration
of the need for collagen and advanced therapeutic agents should be introduced when
wounds fail to achieve sufficient healing after 4 weeks of standard care (Frykberg & Banks,
2015). The care of chronic wounds has become very important, with providing advanced
therapies, including, extracellular matrices (ECMs), growth factors, engineered skin, and
negative pressure wound therapy (NPWT) as a standard of care, etc (Frykberg & Banks,
2015; Rice et al., 2014). Different other studies have shown increased levels of the proinflammatory cytokines like IL-1, IL-6, and MMPs in chronic wounds. Also, a lot of
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studies have proved strong correlations between chronic wounds and these proinflammatory cytokines (Patel, Maheshwari, & Chandra, 2016).
Chronic wounds can be classified as vascular ulcers (venous and arterial ulcers),
diabetic ulcers, and pressure ulcers (decubitus ulcers) (Nunan, Harding, & Martin, 2014).
The most common characteristics shared by each of these chronic wounds are: prolonged
or excessive inflammation (Schultz et al., 2003), persistent infections, formation of
biofilms (bioburden), and the inability of dermal and epidermal cells to respond to
reparative stimuli (Attinger et al., 2006; Demidova-Rice, Salomatina, Yaroslavsky,
Herman, & Hamblin, 2007; Edmonds, 2012; Frykberg & Banks, 2015; A. Stojadinovic,
Carlson, Schultz, Davis, & Elster, 2008; Woo, Ayello, & Sibbald, 2007).

Collagen types:

Collagen is the most abundant protein in the body. It constitutes around ¼ of total
protein in the human body, which is mainly produced by fibroblasts and secreted into the
ECM. Collagen is involved in all phases of the wound-healing cascade. It stimulates
cellular migration and contributes to new tissue development (Fleck & Simman, 2011).
Collagen mainly presents in the bones, connective tissue, tendons, blood vessels,
and skin. In the skin, collagen in conjunction with other proteins such as elastin, forms the
basic flexible and pliable matrix that incorporates living dermal cells, blood vessels,
sebaceous glands, and other components of the extracellular matrix (glycosaminoglycans,
glycoproteins) (Fleck & Simman, 2011).
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Type III collagen is first produced in adult wounds in a form of granulation tissue,
followed largely by type I. However, in fetal and newborn tissue, type III collagen is still
the dominant type of collagen. Collagen is synthesized in fibroblasts and secreted to
support ECM in a triple helix form known as a procollagen. Procollagen has propeptides
attached to the carboxy and amino terminals. At the ECM these monomers self-assemble
into collagen fibrils. Vitamin C is an important factor which is essential for all wound
healing phases (Moores, 2013). Ascorbic acid is also needed for the hydroxylation of
proline and the formation of stable triple helices for collagen formation. Therefore, woundcare professionals should check the nutritional status of chronic wound patients who might
have vitamin C deficiency as the cause of their wound healing delay (Moores, 2013).
Research by Szarka & Lőrincz revealed the possibility of ascorbic acid involvement in
oxidative protein folding and hydroxylation that is needed for collagen and ECM formation
(Szarka & Lorincz, 2014).
Based on many scientific articles, collagen-based dressings could contribute toward
wound healing by changing wound molecular biology levels and may trap more growth
factors that help accelerate the healing process (Fleck & Simman, 2011). Actually,
fibroblasts produce ECM in the form of collagen and that occurs by interaction between
fibroblast and myofibroblast (Werner, Krieg, & Smola, 2007). Many studies reveal the
clear interaction between fibroblasts and keratinocytes (Werner et al., 2007), the latter one
will activate fibroblasts to produce different growth factors. These growth factors basically
will help keratinocyte to proliferate.

5

Growth factors and cytokines literature review:

Table 1: Shows the important Growth Factors and Cytokines Involved in Wound Healing
Growth factor
Abbreviation Source
PlateletPDGF
Platelets,
derived growth
keratinocytes,
factor
fibroblasts,
endothelial
cells,
perivascular cells
Transforming
TGF-β
Platelets,
growth factor-β
keratinocytes,
fibroblasts,
endothelial
cells,
macrophages
Transforming
TGF-α
Platelets,
growth factor-α
keratinocytes
Epidermal
EGF
Platelets
growth factor
Interleukins
IL-1, IL-10
Leukocytes,
keratinocytes

Functions
Fibroblast proliferation, chemotaxis &
collagen metabolism; angiogenesis

Tumor necrosis TNF-α
factor-α
Fibroblast
FGF
growth factor

Leukocytes,
keratinocytes
Keratinocytes,
macrophages

Promotes inflammation

Vascular
endothelial
growth factor

Platelets,
keratinocytes,
macrophages,
neutrophils

VEGF

Fibroblast proliferation, chemotaxis &
collagen
metabolism;
angiogenesis;
immunomodulation

Keratinocyte proliferation & migration
Keratinocyte proliferation & migration
Fibroblast
proliferation;
inflammation

promotes

Fibroblast and epithelial cell proliferation;
matrix deposition, wound contraction;
angiogenesis
Angiogenesis; vascular permeability;
macrophage chemotaxis

Since growth factors and cytokines are very important to wound healing, they have
been extensively studied over the past decades. They contribute and regulate the activity
of the cells in order to accomplish healing as a response to tissue injury (Molloy, Wang, &
Murrell, 2003; Rosique et al., 2015). Complement cascade and various growth factors have
been shown to have a role in the inflammation and have recently been shown to augment
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wound healing. In our study, we investigate around 27 cytokines and growth factors that
many of them have direct relation to wound healing; for example, interleukin- (IL-1a), (IL1b), (IL-6), and tumor necrosis factor (TNF-alpha), which have been linked to regulate the
function of neutrophils and recruit other inflammatory cells toward the wound location.
During the inflammation phase of wound healing, TNF-alpha is a major cytokine secreted
mainly by macrophages and neutrophils. It is elevated in early wound healing and could
stay elevated in chronic wounds and contribute to the inflammation phase (Goel, Kumar,
Singh, & Bhatia, 2010; Rosique et al., 2015; Streit, Beleznay, & Braathen, 2006).
Studies have shown that neutrophils are considered as the fastest eukaryotic cells
because their speed has been measured through an in vitro study and reached 10 μm/min
using two-dimensional (2-D) surfaces (Halilovic, Wu, Alexander, & Lin, 2015; Moghe,
Nelson, & Tranquillo, 1995). Some of these pro-inflammatory cytokines accused for
delaying wounds by degrading the extracellular matrix and growth factors that are
necessary for wound healing and also by inhibiting cell proliferation and migration
(Neuman, Nanau, Oruna, & Coto, 2011). R. Rosique. M. Rosique & Farina, (2015)
mentioned that tumour necrosis factor-alpha antibody (Infliximab) can inhibit TNF-alpha
activity and was effective in treating many chronic inflammatory diseases. In a case series
done by Streit, Markus, Beleznay, & Braathen (2006) were they applied Infliximab
topically to treat 14 patients with chronic venous ulcers for more than a 4-month duration
(Streit et al., 2006). Infliximab was applied as a solution or as a gel formulation and was
repeatedly applied to the ulcers for more than 4 months duration. After 8 weeks, the authors
noted that five ulcers completely achieved healing, while the other four ulcers did achieve
more than 75% of healing rate (Rosique et al., 2015; Streit et al., 2006). Therefore, further
7

studies should be conducted to evaluate the effect of topical Infliximab on chronic wound
healing.
Another growth factor that we analyzed is Fibroblast growth factor (FGF), which
has a crucial contribution in angiogenesis, cell growth, and tissue repair. FGF consists of
22 members, 18 of them are mammalian FGF, which are grouped into 6 subfamilies
according to the differences in their sequence and the range of their biological functions
(Beenken & Mohammadi, 2009; W. H. Lin et al., 2015). China was the first and the only
country in the world for clinical application of FGF-1, FGF-2, and FGF-10 which have
been approved by the SFDA for wound healing. Other therapeutic usages that are
mentioned in the literature interfere with FGF2-induced angiogenesis, for example,
Thalidomide. This medication has been tested and shows in phase II trials that its efficacy
in treating cancer, including renal and prostate cancers, was notable (Beenken &
Mohammadi, 2009; Eisen et al., 2000; Figg et al., 2001).
In our experiment, we tested basic fibroblast growth factor (bFGF), which is the
same as FGF2. Suzuki et al., 2015, showed that bFGF does accelerate wound healing by
enhancing granulation and epithelialization. bFGF is increased mainly in acute wounds (S.
Barrientos, Stojadinovic, Golinko, Brem, & Tomic-Canic, 2008) and different research
papers mentioned that bFGF is responsible for granulation tissue formation by stimulation
of the growth of fibroblasts and endothelial cells. (Greenhalgh, Sprugel, Murray, & Ross,
1990; Powers, McLeskey, & Wellstein, 2000). bFGF was found to be involved in
granulation tissues and new capillary formation (Masuoka, Morimoto, Sakamoto, Ogino,
& Suzuki, 2015). Also, bFGF is considered as an angiogenic factor (Basilico & Moscatelli,
1992) that is needed for angiogenesis (Greenhalgh et al., 1990). FGF-2 works as a
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fibroblast stimulus in an autocrine manner (Powers et al., 2000). Research studies that were
done on diabetic mice db/db have revealed that treatment with human recombinant PDGFBB, bFGF, or a combination of both increased the rate of cellular infiltration and capillary
ingrowth into the wounds of db/db mice. In another study, scientists tested the fibroblast
migration from human dermal skin and they found that it was significantly impaired in
presence of a high glucose level; however, bFGF has increased the number of cells and
enhanced the migration of human dermal fibroblasts in diabetic patients (H. Shi et al.,
2015). Researchers also emphasized in many articles that diabetes itself has negative
effects on the activity of fibroblasts, which mainly affect proliferation and migration
function of fibroblasts (Hehenberger & Hansson, 1997; Hehenberger, Heilborn, Brismar,
& Hansson, 1998). Hehenberger et al. (1998) have addressed in his research that fibroblast
proliferation inhibition and growth factors resistance occur in presence of high glucose
concentrations. Around 4 decades or more, researchers started a clinical trial using
recombinant human basic fibroblast growth factor (RbFGF). Actually, in June 2001 Japan
launched a product named “Fiblast Spray” and it was used to treat pressure ulcers
(decubitus ulcers) and different types of skin ulcers.
One of the growth factors responsible for dermal fibrosis is transforming growth
factor-beta1 (TGF-β1). TGF-β1 induced fibroblast cell proliferation and excessive
accumulation of collagen type I (L. Lin, Wang, Liu, & Huang, 2015). In this paper, Wang
and Huang (2015) run experiments by obtaining keloid tissue donating from a male, 22
years old. After that, they took pieces of keloids and implanted them into subcutaneous
cavity on the 24 nude mice model of keloid (8-week old). Lin et al. (2015) have been
revealed the results of this interesting in vivo experiment after 6 weeks from the injection
9

of BMP and activin membrane-bound inhibitor (BAMBI) which acts as a functional
inhibitor for TGF-β receptor. They have shown that growth of the implanted keloids
significantly diminished through suppressing TGF-β1 after injection of BAMBI.
Therefore, we can infer from this experiment that TGF-β1 has an effective role on
fibroblast cell proliferation and collagen type I production (L. Lin et al., 2015; C. Liu et
al., 2014). Transforming growth factor beta1 (TGF-β1) is a cytokine that has the broadest
spectrum of effects which have involved in a variety of processes like fibroblast
proliferation and differentiation, cellular migration, extracellular matrix (ECM)
production, and cell apoptosis (Finnson, McLean, Di Guglielmo, & Philip, 2013; Roux,
Borbely, Sloniecka, Backman, & Danielson, 2015).
Mainly macrophages and platelets are the main cells contributing to release
transforming growth factor beta (TGF-β) which has a major role as a potent
chemoattractant and activator of fibroblasts that are involved in collagen synthesis. TGF-β
is described in the literature as the best fibrogenic mediator in wound healing. In the study
that was done by Wang et al. (2011) where they added exogenous metalloproteinase 2,
(MMP-2) to the wound culture in vitro and they did close observation to the activity of
ACL fibroblast toward the healing process. What they found is the TGF-β1 was
significantly increased and as a result, it did stimulate ACL fibroblasts to produce more
collagen that was needed for complete wound healing (Wang et al., 2011). Therefore, the
main point that we infer from this experiment is the TGF-β1 has a crucial part of wound
healing by advancing the fibroblast proliferation and migration (Wang et al., 2011). TGFβ family is composed of three main isoforms: TGF-β1, TGF-β2, and TGF-β3, which
formed essentially by interrelated and interconnected dimeric polypeptide chains
10

(Poniatowski, Wojdasiewicz, Gasik, & Szukiewicz, 2015). TGF- β1, in acute skin injury
is mainly secreted from different cell types, such as platelets, keratinocytes, fibroblasts,
and macrophages (Faler, Macsata, Plummer, Mishra, & Sidawy, 2006). On the other hand,
in chronic wounds, TGF-beta levels are low (Robson, 1997) which could be destructed due
to various proteolytic enzymes, like elastase, which are produced mainly from neutrophil
cells that could make these kind of growth factors very low and ineffective in wound
healing (S. M. Chen, Ward, Olutoye, Diegelmann, & Kelman Cohen, 1997).
Interleukin-6 (IL-6) is a proinflammatory cytokine that increased in acute wound
phase and probably mounted in chronic wounds as well. IL-6 also is produced by a variety
of cell types; however, IL-6 receptors are expressed only in a few cells (O'Reilly,
Ciechomska, Cant, Hugle, & van Laar, 2012). IL-6 plays an important role in the
inflammation phase (O'Reilly et al., 2012). Therefore, good level of IL-6 signaling is
needed to kick off the wound healing mechanism. In addition to chronic wounds, IL-6 is
involved in other systemic diseases like chronic inflammatory diseases, such as
inflammatory bowel diseases, diabetes, systemic sclerosis, and asthma (O'Reilly et al.,
2012).
Recent studies suggest the possibility of treating all of these chronic autoimmune
diseases just by blockage of IL-6 signaling (Jones, Scheller, & Rose-John, 2011).
Researchers think that way is a very effective strategy and may be a promising therapy for
such chronic inflammatory diseases and cancer (X. Liu, Jones, Choy, & Jones, 2016;
Neurath & Finotto, 2011). One of the unique functions of IL-6 is acting as an organizer to
the flow of chemokines that are responsible for leukocyte movements. IL-6 also plays an
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important role in shifting from innate to adaptive immunity which ultimately leads to
leukocyte differentiation and proliferation (Jones, 2005; Jones et al., 2011).
Sloniecka, Le Roux, Zhou, & Danielson, (2016) addressed the effect of substanceP (SP) stimulation over the proinflammatory IL-8. IL-8, after being activated, acts as a
chemotactic to inflammatory cells, mainly neutrophils to migrate into wound location
(Sloniecka, Le Roux, Zhou, & Danielson, 2016). Interestingly, IL-8 promotes keratinocyte
migration and differentiation through SP activation. IL8 is produced by epithelial and
fibroblast cells that are the main cells producing IL-8 which is responsible for the
inflammation in the wound healing (Dobreva, Waeber, James, & Widmann, 2006;
Matsushima & Oppenheim, 1989). Baggiolini et al. (1994) emphasised IL-8 aggregation
especially after migration of monocytes to the site of injury and also the strong correlation
between IL-8 and chronic inflammatory conditions in presence of neutrophils (Padrines,
Wolf, Walz, & Baggiolini, 1994).
Previous research studies discussed the fact that especially during the phagocytosis
process, neutrophils produce IL-8 (Bazzoni et al., 1991) after adding LPS to neutrophils;
however, the exact role of neutrophil proteinases in activating IL-8 is still unclear.
IL-8 is secreted by neutrophils in two forms, IL-8(77) and IL-8(72). One contains 77 amino
acids and the other one has 72 amino acids (Bazzoni et al., 1991). Here, Bazzoni, et al.
(1991) explained in his research paper that IL-8 is converted into the active form only after
neutrophils’ protineases-releasing enzymes, like elastase, cathepsin-G and proteinase-3
during the inflammatory phase.
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Many research papers mentioned the function of IL-8 as a chemotactic to
leukocytes and fibroblasts, as well as its huge role contributing in wound healing process
(Dobreva et al., 2006).
Here is another important growth factor called Platelet Derived Growth factor (PDGF)
molecule, which consists of two polypeptide chains connected by an intermolecular
disulfide bond (Hughes, Clunn, Refson, & Demoliou-Mason, 1996). There are five
isoforms of PDGF: PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD
(Gilbertson et al., 2001; Hughes et al., 1996; LaRochelle et al., 2001). PDGF is a
hydrophilic glycoprotein, released by a wide range of cells including platelets,
macrophages, and different other cells like endothelial and vascular smooth muscle cells
(Hughes et al., 1996).
PDGF is considered as a weaker angiogenic growth factor compared to FGF and
VEGF (S. Barrientos, Stojadinovic, Golinko, Brem, & Tomic-Canic, 2008); however,
PDGF is considered as one of the earliest growth factors which acts as a chemotactic to
different cell types responsible for migration and wound healing (Heldin & Westermark,
1999). In addition, PDGF works as a good stimulus to fibroblast cells to proliferate and lay
collagen that is necessary to promote the ECM network as the end result (Clark, 1993;
Heldin & Westermark, 1999).
In our research, we specifically analyzed PDGF-BB type. In the Unites States, the
only randomized clinical trials that were successfully completed until now used PDGF-BB
(S. Barrientos et al., 2008a). In a previous diabetic-mouse model-wound impairment study,
where researchers are used to test some of the growth factors and how they could improve
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wound healing, like PDGF-BB and basic fibroblast growth factor (Greenhalgh et al., 1990).
PDGF has two different receptors: PDGFα receptor and PDGF-β receptor. Interestingly,
the binding specificity of these receptors are different toward the two PDGF chains; for
example, PDGF-A and PDGF-B chains bind to PDGFR-α specifically. While the PDGF-β
receptor binds only to PDGF B-chain type. (Hughes et al., 1996; LaRochelle et al., 2001).
PDGF was approved for clinical use in 1997, and was named commercially as
(Regranex) and the first time was used for treating diabetic foot ulcers. In many clinical
usages of synthetic PDGF, they have shown increasing granulation tissue of cutaneous
wounds. Steed et al. (2006) in their clinical trials have evaluated the efficacy of rhPDGFBB. Application of rhPDGF-BB only one time daily is considered adequate and safe
treating chronic wounds like diabetic foot ulcers (Steed, 2006).
VEGF-A is considered the most potent type of VEGF family, which consists of
other member types: VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEG-F, and placental
growth factor (PLGF). VEGF receptor (VEGFR) expression in the very early time of
literature was thought only present in the endothelial cells, but researchers found out
recently that VEGF receptors can be present and expressed by other cell types like
macrophages and keratinocytes. That clearly indicates that VEGF as a growth factor may
have other roles during wound healing process than was previously believed (Johnson &
Wilgus, 2014). The literature reported that VEGF active levels were significantly low in
people who have chronic wounds (S. Barrientos et al., 2008; Bodnar, 2015; Johnson &
Wilgus, 2014).
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Presence of excessive amounts of inflammatory cytokines/chemokines in the
wound is regarded to be inhibitory to the neovascularization process. On the other hand,
the ability of wounds to form a new vasculature will definitely improve wound healing
(Bodnar, 2015).
Angiogenesis:
Angiogenesis is a process of new blood vessel growth from already existing vessels
(Johnson & Wilgus, 2014). Failure of wounds to form a new vasculature will lead to
inability of wounds to heal. Therefore, this process is considered as an essential step for
successful wound healing. Providing oxygen and nutrients to injured tissues via new
vessels formation (angiogenesis) is crucial for cell growth and ultimate wound healing
(Johnson & Wilgus, 2014). Also, angiogenesis helps tissue to survive after ischemia, and
it supports damaged tissues. Angiogenesis also can be defined as an amplification operation
that happens at the level of already existing microvascular vessels in order to increase tissue
growth and regeneration (Cuevas & Boudreau, 2009). Vascular endothelial growth factor
(VEGF) is considered to be one of the strongest proangiogenic growth factors present in
the skin. Also, the presence of VEGF in the wound can give us a very good indication about
the future of the wound healing course (Johnson & Wilgus, 2014).
Neovascularization is a process of a new blood vessel formation (Bauer, Bauer, &
Velazquez, 2005), which is essential in many physiological conditions including wound
healing, and other pathological conditions, for example, diabetic retinopathy and cancer.
Neovascularization consists of two processes: angiogenesis and vasculogenesis (Djonov,
Baum, & Burri, 2003; Harry & Paleolog, 2003; Z. J. Liu et al., 2003; Patan, 2004).
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The mechanism of angiogenesis occurs in two different ways: intussusception and
sprouting (Flamme, Frolich, & Risau, 1997; Folkman, 1995; Molinas et al., 2003; Paku &
Paweletz, 1991). Sprouting angiogenesis happens after proteolytic enzymes degrade the
basement membrane of small blood vessels. After that, endothelial cells migrate and
proliferate in the ECM. As a result, vasodilation and blood vessel permeability occur. This
type of bud formation that mainly occurs internally and reconnects the lumen of small
blood vessels together, is known as sprouting (Djonov et al., 2003). Caduff et al. (1986)
were the first scientists who addressed the second form of angiogenesis called (nonsprouting or intussusception), which was first discovered after study had been applied in a
rat's lung; they have noticed that pulmonary capillary regrew very quickly (Caduff, Fischer,
& Burri, 1986).
Van Groningen et al. (1991) & Zhou et al. (1998) reported in their research that
intussusception type of angiogenesis can o ccur in myocardium and skeletal muscle
respectively (Djonov et al., 2003).

Pressure Ulcers (PUs):

Pressure ulcers are defined as breaks in the skin or underlying tissue which are
caused by continuous pressure of the body weight against the skin, usually over a bony
prominence. Pressure ulcers has other names: bedsores and decubitus ulcers (Dumville,
Webster, Evans, & Land, 2015). PUs can arise from a combination of shearing and/or
friction against a hard surface. Pressure ulcers are regarded as one of the most frequent
causes of death among elderly and bed-bound patients. (J. M. Levine & Zulkowski, 2015;
S. M. Levine, Sinno, Levine, & Saadeh, 2013; O. Stojadinovic et al., 2013).
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Pressure ulcers can be devastating to patients and families. There are a couple of
factors that can contribute to or cause pressure ulcers which can be divided into two main
groups.


Intrinsic factors, which are mainly within the body, like chronic disease, poor nutrition,
low prealbumin and albumin, elderly, dehydration, bedridden or wheelchair bound.



Extrinsic factors, which include external effects that can cause skin damage such as
friction, shear, or moisture. According to Wound Ostomy and Continence Nurses Society,
2006-2011, injury to the skin or underlying tissue mostly affects certain areas, like sacrum,
ischium, coccyx, heel, and trochanter. Therefore, changing patient position every 2 hour is
very important for the prevention.
We need to know pressure ulcer stages as a key for understanding pressure ulcers clearly
and managing them properly (Black et al., 2007). Pressure ulcers are staged into (Spear,
2013):
Stage I: A stage I pressure ulcer is an area of intact skin. It is a non-blanchable redness of
a localized area over a bony prominence. The area might be painful, firm or soft compared
to adjacent tissues.
Stage II: In this stage, the wound is a superficial, partial-thickness wound that looks like
a shallow open ulcer with partial loss of dermis without slough. The wound bed looks pink
and red.
Stage III: Stage III is a full thickness wound with tissue loss. The subcutaneous tissue may
be visible. Nevertheless, bone, tendon or muscle are not exposed. There can be slough
tissue at the wound bed. Also, undermining and tunneling might be present as well.
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Stage IV: Full thickness tissue loss with palpable bone or tendon and exposed muscle. At
some parts of the wound bed, slough or eschar may be present. Also, undermining and
tunneling are often present in this stage.
Unstageable: It is a full thickness tissue loss. Actually, in this stage the base of the ulcer
is covered by slough or eschar. It is difficult to get an accurate staging until necrotic tissue
is removed.

Prevention measurements:

Management of Pressure ulcers are best prevented in the first instance by using risk
assessment tools and ensuring pressure is relieved frequently, either by turning or using
pressure-relieving mattress devices.
The Braden scale (H. L. Chen, Cao, Wang, & Huai, 2015), which is widely used as
a tool risk assessment by the nurses and wound-care team, provides the information
regarding the individual status and the suitable intervention necessary. Based on the clinical
practice evidence and retrospective research study, there are three risk levels to assess
pressure ulcers. A total score below 11 is considered high risk, scores of 12 to 16 is
moderate risk, and the score of 17 or above is considered mild risk (H. L. Chen et al., 2015).

Pressure Ulcer management based on Braden score:
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Patient with a Braden score of 17 or above (H. L. Chen et al., 2015): We should
encourage patient to change his position if he can. Also, make sure to maximize patient’s
mobility and activity. We encourage the wound-care team to use pressure offloading
surfaces. Braden scores of 12-16 which considered moderate risk: Use the previous
methods plus routine reposition. Also, we should use bolsters or wedges to maintain
position as necessary. Braden score of 11 or less, which is high risk: We recommend
increasing patient’s turning frequency. Wound-team should manage moisture, nutrition,
and keep eyes on friction sites. In addition to that, we should add pressure offloading tools
when the patient is in the bed or in the chair (H. L. Chen et al., 2015).
There is an important phrase to remember, called pressure redistribution that is now
used instead of pressure reduction and pressure relief. Therefore, Braden scale can predict
pressure ulcer by giving us the score risk level which is very effective in pressure ulcer
prevention (H. L. Chen et al., 2015). Also, the gold standard for preventing pressure ulcers
is by repositioning the bedridden patient at least every 2 hours; use pull sheet to pull the
patient and turn him; perform passive range of motion; and elevate the head of the bed to
an angle not exceeding 60º.

Negative-pressure
closure (VAC):

wound

therapy

(NPWT)

/

vacuum-assisted

Morykwas et al. (1997), applied NPWT first as a controlled suction through a
foam to create an environment that promoted wound healing (Malmsjo, Huddleston, &
Martin, 2014). After that, this therapy has successfully become popular and widely
distributed to cover health care centers through the last 18 years. However, the exact
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physiological properties of its effects are not yet fully understood (Kairinos, Solomons, &
Hudson, 2010). NPWT is a very effective modality for treating chronic and difficult
wounds (Argenta & Morykwas, 1997; Morykwas, Argenta, Shelton-Brown, & McGuirt,
1997). Dumville, Webster, Evans, and Land (2015) mentioned that NPWT is a treatment
choice for decubitus ulcers.
NPWT is widely applied to different surgical wounds by creating negative pressure
atmosphere that is needed to drain wound exudate in order to achieve wound healing
(Bradbury, Walkley, Ivins, & Harding, 2015; Ubbink, Westerbos, Evans, Land, &
Vermeulen, 2008). To summarize the main goal of using VAC therapy, is by removing as
much as possible of moisture and drainage from the wound bed, and also other
proinflammatory cytokines/chemokines that are involved in chronic wounds (Greene et al.,
2006; Stechmiller, Kilpadi, Childress, & Schultz, 2006; Trengove et al., 1999).

NPWT Device structure:

NPWT is considered a new technology in wound care. NPWT provides a constant
negative pressure to the wound bed. It consists of five main components: 1- A foam
(sponge) with fenestrated pores which is placed in the wound bed. 2- A semi-permeable
sheet to isolate the wound environment and provide a seal to the wound. Also, it allows the
vacuum system to transmit subatmospheric pressures to the wound bed. 3- Connecting
suction or drainage tube which acts as a connection suction between the sponge and the
canister. 4- NPWT pump or suction device. 5- A canister which keeps exudates and wound
drainage until full and replaced by a new one. The device permits the negative pressure to
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be distributed all over the wound throughout the foam and improves exudate drainage
(Bradbury et al., 2015; Malmsjo et al., 2014).

How does NPWT work?

NPWT is applied directly to the wound bed using an electrical battery, or
mechanically powered pump. NPWT should be applied after the wounds are cleaned,
debrided from any slough or nonviable tissue/eschar. The sterile foam should be cut to fit
the wound size and placed in a wound bed. Also, we make sure that any areas of
undermining or tunneling should also be filled with foam pieces. We recommend using
skin sealant plus padding of periwound area to prevent skin irritation. The wound is
covered with film drape to ensure an airtight seal. The tube clamps are opened, and the
pump is turned on to allow wound exudate and drainage to travel into the collecting
canister.
In our study, we adjusted the pressure to 125 mmHg; similarly, most studies have
used 125 mmHg of pressure as well (Argenta & Morykwas, 1997; Argenta et al., 2006;
Morykwas et al., 1997). Early research done by Morykwas et al., 1997 mentioned the blood
flow improvement to the wound with setting NPWT at higher levels; however, recent
research studies have supported this finding (Borgquist et al., 2011) while other studies
rejected that (Kairinos et al., 2010). Many research studies have mentioned the risk of high
negative pressure that result from the NPWT application, as potential cause of ischemia to
the tissues and adjacent wound structures (Kairinos et al., 2010).
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Studies that done on animals revealed that NPWT may hasten removal of any blood
or serum collection in the wound bed through the lymphatic system (Kilpadi &
Cunningham, 2011). The main things that NPWT provides to wounds as a standard of care
are, elimination of wound exudate, minimizes bacterial colonization, and supports to the
granulation tissue formation (Gupta et al., 2004).
NPWT can be clinically applied for a wide range of wounds; however, NPWT may
have other mechanisms of action depends on the wound type and location. Therefore, in
order to get a better idea of mechanism of action of NPWT, further studies are required
(Malmsjo et al., 2014). Previous study which have mentioned the benefit of applying
NPWT on stage III or Stage IV pressure ulcers, the result have shown great reduction in
the hospitalization and urgent care admission with NPWT treated group compared to other
type of wound treatment (Schwien, Gilbert, & Lang, 2005). Another research article
supports the fact that NPWT is suitable technique for treating stage III and IV decubitus
ulcers (Gupta et al., 2004).
From the literature, also VAC did help shrink the wound surface area which can be
observed including poorly healing ulcers. Also, NPWT is commonly used to treat different
type of pressure ulcers as well (Argenta et al., 2006), and it is regarded as a good option
for treating pressure ulcers (Dumville et al., 2015).

Wounds indicated for NPWT:
1. Acute wounds
2. Chronic wounds (Dumville et al., 2015)
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3. Traumatic wounds
4. Partial Thickness Burns.
5. Dehisced Wounds.
6. Diabetic Ulcers.
7. Pressure Ulcers (Schwien et al., 2005)
8. Flaps and Grafts (Dumville et al., 2015)

Contraindication of using NPWT:
1. Wounds with sloughing and necrotic tissues with eschar present.
2. Osteomyelitis untreated wounds.
3. Exposed blood vessels, nerves, or unexplored fistula.

Passive contraindications:
1. History of bleeding or taking oral anticoagulants
2. Wounds with exposed tendon or bone
To sum up, from the literature, we can say that the application of controlled subatmospheric
pressure creates an environment that promotes wound healing.

Steps to apply NPWT successfully:
First, clean wound by irrigating wound with normal saline or solution. Second,
clean and dry periwound area. Then, apply skin prep to periwound tissue. An appropriate
foam should be selected. Make sure to cut foam away from wound bed, and try to match
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the size of wound. After that, put the sponge into wound bed. The next step, drape to cover
the foam dressing. Make a hole in drape for the suction tube pad placement. Fix the sterile
canister into NPWT and connect suction tube to it. Make sure both clamps are open. Select
NPWT pressure settings and initiate therapy.

Notion of wound dressing:
Winter (1962) demonstrates the concept of active dressing. He states clearly that
moist dressings can accelerate re-epithelialization and wound healing compared to
traditional dry dressings (Stanirowski et al., 2015; WINTER, 1962). They have mentioned
in the literature that wet or moist wounds have shown great stimulation to reepithelization
and decreasing to scar formation comparing to dry wounds (Junker, Kamel, Caterson, &
Eriksson, 2013).
Many research articles have mentioned that dressings should be inexpensive,
simple, and highly absorptive (Sood, Granick, & Tomaselli, 2014). Also, dressings should
have antibacterial properties as well. However, absorptive and antibacterial properties
should be selected according to the wound needs (Dhivya et al., 2015).
The idea of wound dressing is to apply non-harm, non-adhesive and non-allergenic
types of dressing, and should absorb wound exudates and maintain wound moisture (Czaja,
Krystynowicz, Bielecki, & Brown, 2006; Liang, Lu, Yang, Gao, & Chen, 2016). However,
still to our time, there is no specific wound dressing that clinically have met the criteria of
optimal wound dressings. Clinicians and wound-care teams should take into consideration
that ideal dressings must be selected based on two things: risk of infection and
inflammation
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Blood glucose control and good nutrition supply are regarded as important factors
that clinicians should adjust to achieve successful treatment (Sood et al., 2014). Clinicians
and health-care providers nowadays are using a huge variety of wound dressings for
different kinds of wounds. Basically, in the market, probably there are more than 3000
wound dressing products for managing different wounds (Dhivya et al., 2015; Sood et al.,
2014).
Vitamins and minerals affect wound healing; for example, patients who take
steroids, they get benefit of using vitamin A, which helps decrease wound inflammation
and improve healing. Vitamin C is essential for the hydroxylation of lysine and proline in
collagen synthesis and cross-linking. Zinc is a very important cofactor for protein synthesis
and cellular proliferation. Also, zinc is a part of the MMPs’ family of proteases (zincdependent endopeptidases) which have a big role in ECM degradation. Usually zinc
deficiency occurs through wound drainage or gastrointestinal fluid loss like diarrhea
(Lobmann et al., 2002). Essential fatty acids are also needed for all kind of cell synthesis.
One of the other important nutrient factors is protein, which affects wound healing and its
deficiency can retard fibroblast proliferation, ECM, collagen synthesis, and angiogenesis
(Guo & Dipietro, 2010). Trace elements like copper which plays an important role as a
cofactor enzyme is needed for cross-linking of collagen and makes collagen have more
tensile strength. Therefore, in addition to an appropriate dressing to the wound, we should
make sure that these vitamin and mineral supplements are given to patients, to avoid any
complication as a result of inadequacy of intake, especially in malnourished patients.

Phases of wound healing:
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Wound healing involves four integrated and overlapping phases which include,
homeostasis, inflammation, proliferation, and remodeling (& MD, and Thomas A. Mustoe,
MD, FACS, ; Gosain & DiPietro, 2004).

Homeostasis:
After the injury, blood-vessel constriction and platelet aggregation occur at the injury site.
After that, a fibrin clot forms, which will minimize blood leak and secure the bleeding.
Fibrin clot contains important molecules, for example, fibronectin, thrombospondin, and
many growth factors. Some of the important growth factors secreted by the clot are:
platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β), fibroblast
growth factor (FGF), epidermal growth factor (EGF), and insulin-like growth factor-1
(IGF-1) (Clark et al., 1982). Also, platelets contain a huge storage amount of growth factors
like TGF-beta, PDGF, and VEGF which are necessary for promoting tissue healing and
enhancing the blood vasculature to the wound area (Sanchez, Anitua, Orive, Mujika, &
Andia, 2009). Furthermore, the clot acts as a glue which helps cells to bind to ECM
proteins. Also, the clot works as a bridge for cells to migrate and cross over during wound
healing (Werner & Grose, 2003).

Inflammatory phase:
Neutrophils and macrophages are the main inflammatory cells that start this phase. Also,
they act as chemotactic agents to other cells that will enhance the inflammation (& MD,
and Thomas A. Mustoe, MD, FACS, ; Dyugovskaya, Berger, Polyakov, Lavie, & Lavie,
2016).Neutrophils in this phase act as a cleaner of any cellular debris (& MD, and Thomas
A. Mustoe, MD, FACS, ) Also, neutrophils help in phagocytosis of bacteria and tissue
debris in the wound area; however, neutrophils can cause more damage by releasing
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proteases, which can extend the inflammatory phase and delay wound healing (Ghatak et
al., 2015). The most advanced wound therapy is focusing on reducing the inflammatory
phase to make wounds heal faster. In normal healing wounds, neutrophils will be engulfed
by macrophages and terminated within the first 48hrs (Broughton, Janis, & Attinger, 2006;
Campos, Groth, & Branco, 2008; Ghatak et al., 2015; Gosain & DiPietro, 2004). Scientists
nowadays are using exogenous growth factors and cytokines for treating chronic wounds
in order to shift this phase, inflammatory, to the proliferative phase (Menke et al.,
2007). As we know failure of progression from inflammatory phase to the other phases
will remain stuck at the same phase, vicious cycle (Mast & Schultz, 1996), and chronicity
will definitely occur.

The Proliferative phase:
This phase can be extended from 4 to 12 days. Macrophages in this phase play an
important role to decrease inflammation. In addition, macrophages are a very rich source
of growth factors and cytokines which are needed for wound healing (Ghatak et al., 2015).
Therefore, macrophages have big role for shifting from inflammatory to proliferative
phase. During this phase also T- Lymphocyte plays a crucial role; however, its role is not
fully understood. Some studies mentioned that T- helper cells have a positive role in wound
healing, whereas T-suppressor cells have the opposite action on wound healing (Ghatak et
al., 2015). Collagen is produced in this stage by fibroblasts which will enhance wound
structure and ECM. Angiogenesis is an important factor that is required in order for tissue
to get a new blood supply to bring nutrients and oxygen to the tissue and support fibroblast
proliferation and allow keratinocytes to enhance epithelialization of the wound (Bodnar,
2015).
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Maturation and Remodeling phase:
Usually this phase starts after 2 to 3 weeks and can continue up to 24 months. At
this phase, matrix metalloproteinases (MMPs), which are proteolytic enzymes, act to
degrade extracellular matrix (ECM) and break down the collagen, and the net result of that
is a balance between collagen degradation and collagen synthesis. There are two main
things that are important to consider in cases of newly formed wounds, with a newly
deposited collagen, which include wound strength and mechanical integrity. Also, in this
phase, angiogenesis, cell migration, differentiation, and at the end collagen production
toward building ECM, are considered a part of the remodeling mechanism (Hodde,
Badylak, Brightman, & Voytik-Harbin, 1996).

Biology of cytokines:

Cytokines are defined as small sized proteins produced by a variety of cells
communicating with host cells via signaling to accomplish a specific function to the tissue
and the immune system (Blackwell & Christman, 1996). Cytokines are considered the
regulatory key that operates the communication between the innate and acquired immunity
via sending signals between the immune system and tissues in cases of inflammation.
Cytokines are considered as specialized cells or messengers that convey signals; for
example, IL-2 promotes T cells proliferation and differentiation, GM-CSF and G-CSF
affect macrophages, and different other cytokines: IL-1, IL-6, IL-8, and TNF-alpha are
responsible for the acute phase inflammation (Ghosh, May, & Kopp, 1998).
Cytokine signaling occurs in four different patterns: Endocrine, paracrine, autocrine, and
juxtacrine depending on the body needs.
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The main purpose of studying cytokine biology is to show how these cytokines act
at the level of gene transcription and how these cytokines can suppress each other via
signals and feedback mechanisms. Also, a lot of cytokine mechanisms and signal
transductions are still not clearly understood; however, many ideas were applied in this
field by creating models to make understanding of cytokines signal transmission better and
make it easy for different quantitative measures (Schmitz, Weber, Roxlau, Gaestel, &
Kracht, 2011).
Anti-cytokine, in a form of antibodies or immune-modulating treatment, is promising for
treating different chronic inflammatory and autoimmune diseases.

MMPs and chronic wounds:
In normal wound healing, MMPs are very essential for degrading ECM, but in a
very moderate precise manner. As the literature mentioned, excessive MMPs will definitely
delay wound healing (Gibson & Schultz, 2013). Researchers pointed out to MMPs as the
direct cause of destroying different growth factors, and cell surface receptors for these
growth factors as well. As a result, cells will lack a communication with each other, with
ECM, and will never show any response to normal growth and repair signals. In addition
to that, with different affinity of growth factors’ binding to extracellular matrix and the
great chance that these growth factors get degraded by the MMPs. All of that can
negatively impact on the concentration of growth factors present in the wound bed. As a
result, wounds will be very challenging to heal on time (Greenhalgh et al., 1990).
Researchers found out that high percentage of MMPs can dehisce acute wounds (Mast &
Schultz, 1996; Trengove et al., 1999). Increasing MMPs can occur by various different
mechanisms though MMPs are mandatory for normal wound cure and tissue revival
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(Lobmann et al., 2002). Another important thing in order to achieve wound healing,
equilibrium should occur between collagen deposition and other ECM degradation
products like MMPs and their inhibitors, tissue inhibitors of metalloproteinases (TIMPs)
(Kahari & Saarialho-Kere, 1997; Madlener, 1998; Ravanti & Kahari, 2000).
The MMPs are produced by different cell types, like macrophages, endothelial
cells, and fibroblasts. MMPs family is composed of around 20 members that have been
distinguished so far (Ravanti & Kahari, 2000). MMPs are considered as zinc-dependent
motives that are strongly expressed in chronic wounds and are involved in ECM
degradation. There are important inhibitors to the MMPs known as TIMPs. Lobmann et
al., 2002 in their study implied that concentrations of TIMP-2 protein were approximately
threefold lower in the diabetic ulcers than in the acute wounds.
Another study that was done on chronic pressure ulcers where the collected fluid
samples from these ulcers were analyzed and have shown notable increase in the amount
of pro-inflammatory cytokines and active proteases such as MMPs; whereas they showed
far less concentration of growth factors, less activity, and reduced TIMPs as well (Mast &
Schultz, 1996).
Major sources of TGF-β include platelets, leukocytes, bone cells and placental
tissue. TGF-β1 can be both inhibitory and stimulatory and is a potent chemoattractant for
monocytes, macrophages, lymphocytes, neutrophils, fibroblasts, and keratinocytes
(Peplow & Chatterjee, 2013). Also, TGF-β1 stimulates the release of different cytokines
(e.g. IL-l, IL-6, TNF-Alpha, and bFGF) from these cells (Lafyatis et al., 1990).
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Many previous studies that had been conducted in vitro assays demonstrated the
fact that TGF-B3 has similar activities to TGF-Β1 and TGF- B2; however, it is not exactly
the same (Lafyatis et al., 1990). Interestingly, many research articles have shown that
TGFβ1 and its receptors are highly expressed in acute wounds, while in chronic wounds
its expression is markedly reduced. (Pastar et al., 2010). TGF-β1 is a master regulator of
fibroblasts mitogenesis, cell growth, and apoptosis. TGF-β3 has shown enhanced scarless
healing in the fetus and minimal scarring in adults while TGF-β1 may be responsible for
fibrosis in adult wounds (Lichtman, Otero-Vinas, & Falanga, 2015).
Research studies have mentioned the strong suppression effect of TGF-beta on T
cells (Wahl, Allen, Wong, Dougherty, & Ellingsworth, 1990), and also TGF-beta is
responsible for decreased activation and proliferation of other cytokines; for example,
TGF-Beta downregulates IL-1 receptors (Wahl et al., 1988) at the level of different cells.

Biochemical and physiological characteristics of Oasis-Ultra:
OASIS-ultra; Cook Biotech, Inc., West Lafayette, IN; exclusively marketed by
Smith and Nephew, Inc., Fort Worth, TX) is an extracellular collagen-rich matrix derived
from porcine small intestinal submucosa (SIS) (AbouIssa, Mari, & Simman, 2015). Oasisultra is known by this name because it consists of a biocompatible, acellular,
nonimmunogenic, and biodegradable tri-layer of porcine small intestine submucosa (SIS)
with thickness of ∼0.30 mm (Cazzell, Lange, Dickerson, & Slade, 2015).
The composition of Oasis-ultra is mostly collagen, around 90%. The majority of it
is type I, and less amount of collagen type III, IV, V, & VI (Badylak et al., 1995), and other
ECM proteins, such as glycoproteins and glycosaminoglycan which are crucial for wide
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range of wound functions. Oasis-ultra acts as a native tissue scaffold; not only it provides
support to the structure, but also provides other vital functions to the wounds; for example,
it has a very important contribution in stimulation of cell proliferation and migration, as
well as minimizing the inflammation that results from proinflammatory cytokines
(AbouIssa et al., 2015). Ahn, et al. (2007) mentioned in their study using SIS as a scaffold
treatment for human bone marrow stem cells, SIS contains glycosaminoglycans,
chondroitin sulfates, fibronectins, hyaluronic acids, heparins, and heparin sulfates. Also, it
has other types of growth factors like basic fibroblast growth factor (bFGF), transforming
growth factor (TGF-), epidermal growth factor (EGF), vascular endothelial growth factor
(VEGF), and insulin-like growth factor-1 (IGF-1) (Huang, Liu, Huang, & Liu, 2014);
however, in our present study, we found out when we analyzed the Oasis-ultra (the three
layer-SIS) using the Bio-Plex system, it just has bFGF and GM-CSF; but the wet form of
SIS might have more growth factors retained.
Also, Oasis-ultra is characterized by easy absorbability and handling, which makes
it suitable as a xenogenic tissue replacement that closely mimics the natural ECM. SIS
showed great tissue remodeling when it was applied in different animal models, such as
vascular, dermatological, urological, and orthopedic wound injuries (Hodde et al., 1996).
There are many factors that could affect Oasis-ultra remodeling behavior when it was
applied in vivo, such as local tissue situation, the rate of ECM degradation, forces at the
level of wound, and the ability of cells to deposit new collagen toward the ECM (Badylak,
Freytes, & Gilbert, 2009).
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Usage of Oasis-Ultra:
Since Oasis-ultra is composed of rich collagen-biomaterials that mimic ECM, with
low antigenicity; that makes Oasis-ultra a good collagen-based matrix to heal different
types of wounds (AbouIssa et al., 2015). For example, Oasis-ultra was successfully applied
in different kinds of wounds, such as, vascular ulcers, diabetic ulcers, vasculitis at achilles
tendon, stage IV pressure ulcer, post-traumatic wound, and post-marjolin’s ulcer excision
(AbouIssa et al., 2015), and partial-thickness and full-thickness wounds. Therefore, Oasisultra successfully healed different types of wounds by up-regulating the important growth
factors necessary and restitution of the old ECM to make wound healing fast and ultimate.
The ability of Oasis-ultra as collagen rich matrix, to deliver certain growth factors to the
wound cells, makes it a wonderful and promising type of wound-dressing treatment (Huang
et al., 2014).
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Hypothesis and Specific Aims:
Hypothesis:

Treating chronic wounds with Oasis-ultra may alter the molecular environment of the
wound by disrupting the prolonged inflammatory phase and allowing normal progression
of the healing cycle.
Specific aims:

1- To test the hypothesis that Oasis-ultra treatment would improve the healing
rate of chronic wounds when compared with the NPWT only.

2- To test the hypothesis that Oasis-ultra treatment would decrease
proinflammatory cytokines and increase the growth factors needed to
achieve wound healing.
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Materials and Methods:
The study was a prospective, multi-centred, randomized, single-blinded clinical
trial that approved by the Ethics Committee of the Copernicus. Written informed consent
was obtained from all patients. We discussed and answered patients’ concerns before
obtaining the consent. Twelve patients enrolled into the study: six were placed in a control
group, receiving only negative pressure wound therapy (NPWT) and the rest of the patients
were selected as a study group receiving both treatment: Oasis-ultra and NPWT. Both
devices are cleared for use by the U.S. Food and Drug Administration (FDA). However,
the use of both devices together is considered investigational in this study. Subjects will be
in the study for approximately 3 months. The canister that contained the wound exudate
was taken every month to the lab. Wound exudates were extracted from the canisters and
aliquoted to 1.5 ml eppendorph tubes along with the addition of a protease inhibitor and
stored at -80°C until use. At wound center, during the weekly examinations, we did
measurements and took photos of the wound. The inclusion and exclusion criteria were:

Inclusion criteria:
1. Adults aged 18-89 who exhibit stage III or IV trunk pressure wounds with no signs of
infection.
2. HbA1c < 8 (if a patient is diabetic)
3. Adequate nutrition including albumin ≥ 2.0 and prealbumin ≥ 12.5.
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Exclusion criteria include:
1. Subjects who have wounds that cannot have a NPWT device properly applied due to
location (too close to anus), or due to other causes, such as diarrhea and peri-wound
skin issues.
2. Patients with infected wounds.
3. Patients with HbA1c >8.
4. Malnourished patients.
5. Immunodeficient or immunocompromised patients.
6. Patients who have a religious or ethical aversion to porcine products or any allergy.
7. Patients who are at risk of bleeding.
8. Patients who are DNR/DNI.
9. Lab results for albumin and prealbumin up to 30 days prior to enrollment and HbA1c
results up to 100 days prior to enrollment were further examined for determination of
their eligibility.
For three months, wounds were measured weekly until the end of the study in terms
of wound closure and the healing rate. Dressings were changed twice a week or more as
necessary at the physician’s discretion. Drainage canisters were collected monthly for the
following three months. The skin surrounding the wound was cleaned and prepped well
before we applied the Oasis-ultra in the study group. Then, we put Adaptec or alginate for
protecting oasis-ultra before we put the sponge. After that, the vacuum assisted closure
foam dressing was trimmed to match the size of the wound and placed directly over the
Oasis-ultra and protective layer. In control subjects, we put the foam directly over the
wound bed. The skin adhesive prep was applied to the skin around the wound
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approximately 3-5cm away from the wound edge and allowed to dry. Next, the appropriate
size of adhesive drape was applied. Then, the suction tube was applied to a small opening
made in a dressing area and was sealed tightly. The tube then was connected to a vacuum
machine, which had a canister to collect the wound exudate. The machine was set to
pressure 125 mm Hg. NPWT was changed 3 times a week in a control group, while in a
study group, it was recommended to be changed 2 times a week. During the three-month
period of the study, the canisters were collected 3 times. If the seal failed before the followup time, the wound-care team changed the dressing and reapplied the NPWT as needed to
keep the wound sealed.

Growth Factors and Cytokine Analysis:

For cytokine analysis using the Bio-PLex system, wound exudate was extracted
from the canisters and aliquoted to 1.5 ml eppendorph tubes; 100µl of protease inhibitor
were added and stored at -80°C until use. For cytokine analysis, 100µl 1XPBS were added
to the sample, and protein concentration was determined using the Bradford assay. A (BioRad) BioPlex 96 well plate was set up with 50 ml of the sample and duplicated for cytokine
analysis using Bio-Plex (Bio-Rad) Human Cytokine 27-Plex Group 1 assay kits. To each
well, buffer, magnetic beads were added and washed on the magnetic plate washer. The
plate was run on the Bio-Plex 200 system at a low PMT setting followed by high PMT
according to Bio-Rad instructions, and the data were grouped using the BioPlex software
package. The data was then analyzed using SPSS software and GraphPad Prism5.
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TGF-Beta Analysis: TGF-β1, TGF-β2, & TGF-β3
For TGF-Beta family analysis, the Bio-PLex system protocol was repeated: wound
fluid was extracted from the canisters and aliquoted to 1.5 ml eppendorph tubes, 100µl
protease inhibitors were added and stored at -80°C until use. For TGF-betas analysis, 100µl
1XPBS were added to the samples, and protein concentration was determined using the
Bradford assay. A (Bio-Rad) BioPlex 96 well plate was set up with 50 µl of the sample and
duplicated for cytokine analysis using Bio-Plex (Bio-Rad) Human TGF-β1, TGF-β2, and
TGF-β3 Plex assay kits. To each well, buffer, magnetic beads were added and washed on
the magnetic plate washer. The plate was run on the Bio-Plex 200 system at a low PMT
setting followed by high PMT according to Bio-Rad instructions, and the data were
grouped using the BioPlex software package. The data were analyzed using SPSS software
and GraphPad Prism5.
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Table 2: Demographic features of patients participating in this study
Total number/ 12
6
6
Variables
Control
Oasis-ultra + NPWT
Male
2
4
Female
4
2
Age
62.5 year
63.5 year
Race
white
white
Alcohol
1 patient drinks around 4 cup/day
N/A
5 out of 6 drink average of 1.8 cup 5 out of 6 drink average of 2.2
Caffeine
of coffee/day
cup of coffee/day
Smoking
N/A
N/A
Weight
75.74kg
86.02kg
BMI
27.85 kg/m
28.69 kg/m
Albumin
3.05mg/dl
2.58mg/dl
Prealbumin
22.21mg/dl
17.51mg/dl
HbA1C
7.0 mg%
7.02 mg%
5 candidates had wound at sacrum
Wound Location
Sacrum
and only one is in the Lt. Ischium
Wound duration
25.6 weeks
19.6 weeks
prior to enrolment
2

2

Statistical Analysis
Results are expressed as means ± SEM. Differences between 2 groups were performed by
multiple comparisons and were analyzed by 1 or 2-way ANOVA. For all tests, a P<0.05
was considered significant. All comparisons were performed using the statistical package
SPSS 16.0 for Window and Prism5.
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Results:
Patient demographics and baseline features presented in table 1. The total number
of patients who have been screened during the time frame of 8/5/2014-10/9/2015 were 63
subjects and 21 were enrolled; 12 patients completed the study successfully, and 8 patients
were excluded from the study.
The healing rate was analyzed over a period of time with weekly measurements
taken from 0 to 12 weeks (Table 3). The ANOVA for difference in groups was not
statistically significant, but it is close to be considered significant; therefore, further study
ought to be done with a larger sample size. Using these data, a boxplot that shows the
healing rates for the two groups was done (Figure 6).

Table 3: Average of the closure% in the study determined over a 12 week period.
Dependent Variable: Healing rate
Groups
Mean
Std. Deviation
N
55.29
38.91919
6
Control
9.63933
6
Oasis
86.59
70.94
31.59039
12
Total
Oasis vs Control: F (df,df) 3.657 (1,10);p-value 0.085; Est. effect size 0.268; Observed power
0.409
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Table 4: Comparison of the healing rate between the two groups at different times.
4-8weeks
Groups
0-4 weeks
8-12weeks
Control
9.4cm³/week
4.43 cm³/week
0.3

12.8 cm³/week

Oasis

14.3 cm³/week

cm³/week
5.4
cm³/week

N
6
6

Healing rate in wounds treated with Oasis-ultra increases in the 4-8 week window compared
to NPWT alone. In addition, the healing rate slows down but continues from 8-12 weeks in
Oasis-ultra treated groups compared to the control group where the healing rate almost
stopped at 8 weeks.

Wound Healing Rate
200
surface area (cm³)

Control
150

Oasis

12.8cm³/week

100

14.3cm³/week
9.4cm³/week
5.4cm³/week
4.43cm³/week
0.3cm³/week

50

0

0

4

8

12

weeks
Figure 1. Healing rate in wounds treated with OASIS-ULTRA increases in the 4-8 week window compared
to NPWT alone even though the size of the wound is 2X larger in the Oasis-ultra treated group. Also, the
healing rate slows down but continues from 8-12 weeks in OASIS-ULTRA treated groups compared to the
group treated with NPWT alone where the healing stopped at 8 weeks.
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Figure 2. The oasis group had a lower variability, meaning that the healing was going on for those six patients
at a steadier rate. For the control group, the variability nearly covered the entire scale (0% to 100%) meaning
that the healing could progress at nearly any rate. Even though, the average wound size of the study group
was 161.36, and of the control group was 72.83, the healing rate of the Oasis treated group was significant
compared to the control group.
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Control group

Oasis group
ontrol group

ontrol group

Figure 3. The wound size of the control group vs. the oasis-treated group during week 0.
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0 week

4 week

8 week

4 week

12 week
week

Figure 4. Stage IV pressure wounds randomized as a study candidate received Oasis-ultra plus NPWT
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Week 0

Week 0

Week 8

Week 4

Week 12

Figure 5. Shows stage IV pressure ulcer which completely healed after 11 applications of Oasis-ultra plus
NPWT.
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87 %

Closure %

55 %

Control

Oasis

Figure 6. This box plot is showing the closure % achieved by the two groups; it is clear that the median
healing rate for the oasis group is much higher than the median healing rate for the control group, and the
variability for the two groups is significantly different.

According to previous reports, several key cytokines were found to have been
changed in wound healing. We chose to use the Bio-Plex (Bio-Rad) system for analyzing
cytokine levels from the wound exudates (lavage). There were 27 different cytokines
analyzed using this assay plus the TGF- βs (Table 5).
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Table 5: Cytokines analyzed in the Human Cytokine 27-Plex Group 1 Assay.
FGF basic
IL-2
IL-10
MIP-1α
Eotaxin
IL-4
IL-12
MIP-1β
G-CSF
IL-5
IL-13
PDGF-BB
GM-CSF
IL-6
IL-15
RANTES
IFN-γ
IL-7
IL-17
TNF-α
IL-1β
IL-8
IP-10
VEGF
IL-1ra
IL-9
MCP-1 (MCAF)
TGF-β1
TGF-β2
TGF-β3

In the previous reports, the cytokines reported in the following tables and graphs
were indicated to have changed during wound healing. We are showing their results,
whether they were statistically significant or not, i.e.: IL-1Ra, IL-1b, IL-6, IL-8, MCP-1,
MIP-1α, VEGF, bFGF, PDGF-BB, and TGF-β1. All cytokine levels were normalized to
total protein levels that were determined by Bio-Rad (Bradford) protein assay.

ANOVA results IL-1Ra:
When IL-1Ra was analyzed, there was a statistically significant difference between
the control and experimental groups; the p-value= 0.05. The significant difference was
observed between control and experimental groups during weeks 4 and 8.
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Table 6: IL-1Ra was not significantly changed during wound healing during the 12 week
period.
Week Control
Oasis
n
Mean
St. dev.
n
Mean
St. dev.
6
474.77
410.46
6
2010.93
1421.14
4
6
951.48
1642.07
6
3506.19
2755.59
8
6
448.95
712.88
6
2021.27
3081.51
12
F (df,df) 4.607 (1,10); p-value= 0.05; Est. effect size 0.315; Observed power 0.492

ANOVA results IL-1b:
The ANOVA for the effect over time is statistically significant. The ANOVA for the
interaction between weeks and the experimental group is not statistically significant.
Finally, the results of the test between the control and oasis groups were analyzed.
The results are shown in the table 7:
Table 7: IL-1b, there were no statistically significant difference between the control and
the experimental groups.
Week
4
8
12

Control
n
6
6
6

Oasis
Mean
1998.68
1753.06
1196.67

st. dev.
1773.82
1588.87
970.40

n
6
6
6

Mean
2170.42
2762.03
1725.57

st. dev.
1143.33
1078.33
1315.54

F (df,df) 0.639 (1,10); p-value= 0.443; Est. effect size 0.060; Observed power 0.112

ANOVA results VEGF:
For a two-way and repeated measures analysis, ANOVA was used. The results are
presented in the following table: Neither the ANOVA for measurements at 4, 8, and 12
weeks nor the analysis of the interaction between the control and the experimental groups
are statistically significant.
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Table 8: VEGF, there were no statistically significant difference between
and the experimental groups.
Week
Control
Oasis
n
Mean
st. dev.
n
Mean
6
315.13
568.39
6
107.31
4
6
77.96
146.75
6
171.24
8
6
73.29
62.22
6
65.03
12

the control

st. dev.
145.65
265.35
83.56

F (df,df) 0.172 (1,10); p-value= 0.687; Est. effect size 0.017; Observed power 0.066

ANOVA results FGF basic:
For a two-way and repeated measures analysis, ANOVA was used. The results are
presented in the following table. Neither the ANOVA for measurements at 4, 8, and 12
weeks nor the analysis of the interaction between the control and the experimental groups
are statistically significant (the p-value was 0.73).
Table 9: bFGF, there were no statistically significant difference between the control and
the study group.
Week
Control
Oasis
n
Mean
st. dev.
n
Mean
st. dev.
6
46.92
35.33
6
23.71
38.54
4
6
27.42
31.92
6
99.36
167.46
8
6
25.59
33.53
6
9.35
14.98
12
F (df,df) 0.124 (1,10); p-value=0.732; Est. effect size 0.012; Observed power 0.062

ANOVA results PDGF-bb:
For a two-way and repeated measures analysis, ANOVA was used. The results are
presented in the table 10: Neither the ANOVA for weeks nor the one for the interaction
between weeks and experimental group are statistically significant.
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There is no statistically significant difference between the control and the experimental
groups. While performing the Kruskal-Wallis tests, separate tests were done for the groups
during the periods of 4 weeks, 8 weeks, and 12 weeks. The results did not show significant
differences between the control and the experimental groups on week 4 or 8, but there was
a significant difference during 12 weeks.
Table 10: PDGF-bb, there were no significant differences between control and
experimental groups at 4 or 8 weeks, but there was a significant difference at 12 weeks.
Week
4
8
12

Control
n
6
6
6

Mean
24.20
11.32
41.93

st. dev.
28.04
9.15
52.69

Oasis
n
6
6
6

Mean
31.56
28.52
2.30

st. dev.
54.36
52.22
2.93

F (df,df) 0.146 (1,10); p-value=0.710; Est. effect size 0.014; Observed power 0.064

ANOVA results IL-6:
The ANOVA for difference in weeks is not statistically significant, even though the means
vary greatly. Again, this is likely due to the immense variance of both groups.
Table 11: IL-6, there was no statistically significant difference between the control and
experimental groups.
Week

Control
n
6
6
6

Oasis
Mean
5036.11
148.711
2796.21

st. dev.
8227.51
232.89
6430.85

n
6
6
6

Mean
104.31
1732.62
20.34

4
8
12
F (df,df) 1.653 (1,10); p-value=0.228; Est. effect size 0.142; Observed power 0.214
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st. dev.
145.37
2979.43
20.81

ANOVA results IL-8:
For a two-way and repeated measures analysis, ANOVA was used. While the ANOVA for
weeks was not significant, the one for the interaction between weeks and experimental
group was statistically significant at week 8. There were no significant differences between
control and experimental groups at 4 or 12 weeks, but the difference at 8 weeks is
statistically significant, p-value = 0.02.
The results are presented in the table 12:
Table 12: IL-8, There were no significant differences between control and experimental groups
at 4 or 12 weeks, but the difference at 8 weeks is statistically significant, p-value = 0.02.

Week
4
8
12

Control
n
Mean
6
2749.24
6
1193.69
6
2050.58

Oasis
n
Mean
6
3216.87
6
5148.94
6
3665.58

st. dev.
2958.83
1915.48
1713.33

st. dev.
2837.87
5957.32
5597.86

F (df,df) 0.896 (1,9); p-value=0.024; Est. effect size 0.091; Observed power 0.136

ANOVA results of TGF-Beta 1:
For a two-way and repeated measures analysis, ANOVA was used. One way ANOVA
shows significant difference on week 4 and 8 were healing mostly achieved at this time.
The results are presented in the table 13.
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Table 13: TGF-β1.
Week
Control
n
Mean
6
0.40
4
6
0.57
8
6
8.92
12

Oasis
n
6
6
6

st. dev.
0.98
1.41
16.77

Mean
33.38
26.29
20.15

st. dev.
70.29
64.41
23.16

F (df,df) 2.937 (1,10); p-value=0.117; Est. effect size 0.227; Observed power 0.341

ANOVA results MIP-1a:
There were no significant differences between control and experimental groups at 4 weeks,
but the difference at 8 weeks is statistically significant, and the difference at 12 weeks is
worthy of further study.
Table 14: MIP-1a.
Week

Control

Oasis

n

Mean

st. dev.

n

Mean

st. dev.

4

6

95.89

175.23

6

32.04

45.41

8

6

5.28

3.78

6

17.35

10.88

12

6

82.77

178.60

6

4.41

1.80

F (df,df) 1.893 (1,10); p-value=0.199; Est. effect size 0.159; Observed power 0.238
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ANOVA results MCP-1:
There were no significant differences between control and experimental groups at 4, 8, or 12
weeks.

Table 15: MCP-1 (MCAF). Neither the ANOVA for weeks nor the one for the interaction
between weeks and experimental group are statistically significant.
Week

Control
Oasis
n
Mean
st. dev.
n
Mean
st. dev.
6
185.90
232.17
6
94.59
188.74
4
6
20.79
36.38
6
60.16
117.11
8
6
141.70
207.20
6
1.17
1.86
12
F (df,df) 1.176 (1,10); p-value= 0.304; Est. effect size 0.105; Observed power 0.166

Here are tables for the most relevant growth factors and cytokines involved in wound
healing, taken at 4, 8, and 12 weeks. (Table 16) is for the control group and (table 17) is
for the Oasis treated group.
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Table 16: The control group for the most important growth factors and
cytokines involved in wound healing analyzed at 4, 8, and 12 weeks.

Analyte
MIP-1b

Week N
4 6
8 6
12 6
IL-6
4 6
8 6
12 6
IFN-g
4 6
8 6
12 6
IL-1ra
4 6
8 6
12 6
GM-CSF
4 6
8 6
12 6
TNF-a
4 6
8 6
12 6
IL-1b
4 6
8 6
12 6
FGF basic
4 6
8 6
12 6
VEGF
4 6
8 6
12 6
PDGF-bb
4 6
8 6
12 6
MCP-1
4 6
8 6
12 6
IL-8
4 6
8 6
12 6
MIP-1a
4 6
8 6
12 6
G-CSF
4 4
8 4
12 4

Mean
409.33
43.01
239.65
5036.11
148.71
2796.21
52.70
40.24
30.72
474.77
951.48
448.95
66.09
56.30
53.89
112.44
47.52
52.28
1998.68
1753.08
1196.67
46.92
27.42
25.59
315.13
77.96
73.29
24.20
11.32
41.93
185.90
20.79
141.70
2749.24
1193.69
2050.58
95.89
5.28
82.77
1112.36
123.79
950.54
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S.E.M
189.31
17.98
161.22
3358.86
95.07
2625.38
18.59
20.42
8.15
167.57
670.37
291.03
17.21
16.61
10.44
67.05
27.55
22.66
724.16
648.65
396.16
14.42
13.03
13.69
232.04
59.91
25.40
11.44
3.73
21.51
94.78
14.85
84.59
1207.93
781.99
699.46
71.53
1.54
72.91
617.37
73.46
894.53

St. dev.
463.72
44.06
394.91
8227.51
232.89
6430.85
45.55
50.02
19.96
410.46
1642.07
712.88
42.17
40.70
25.59
164.25
67.50
55.52
1773.82
1588.87
970.40
35.33
31.92
33.53
568.39
146.75
62.22
28.04
9.15
52.69
232.17
36.38
207.20
2958.83
1915.48
1713.33
175.23
3.78
178.60
1234.74
146.92
1789.06

Median
309.87
23.94
91.50
1347.48
23.47
10.06
39.21
20.17
35.19
481.78
164.75
236.02
75.57
65.36
53.32
23.77
15.09
42.66
1883.11
1336.13
1094.13
34.85
18.50
15.03
102.49
23.50
85.97
10.41
11.94
17.95
88.66
1.97
42.47
1491.15
492.80
1125.22
11.27
4.78
9.79
770.79
67.15
75.42

Table 17: The study group for the most important growth factors and
cytokines involved in wound healing analyzed at 4, 8, and 12 weeks.
Analyte

MIP-1b

IL-6

IFN-g

IL-1ra

GM-CSF

TNF-a

IL-1b

FGF basic

VEGF

PDGF-bb

MCP-1

IL-8

MIP-1a

G-CSF

Week N Mean

4
8
12
4
8
12
4
8
12
4
8
12
4
8
12
4
8
12
4
8
12
4
8
12
4
8
12
4
8
12
4
8
12
4
8
12
4
8
12
4
8
12

6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
5
6
6
6
6
6
2
2
2

338.41
139.55
64.19
104.31
1732.62
20.34
21.82
43.25
15.55
2010.93
3506.19
2021.27
56.11
54.99
81.21
33.88
43.16
17.93
2170.24
2762.03
1725.57
23.71
99.36
9.35
107.31
171.24
65.03
31.56
28.52
2.30
94.59
60.16
1.17
3216.87
4803.05
3054.54
32.04
17.35
4.41
1997.42
4258.21
534.02
55

S.E.M

St. dev.

Median

262.75
65.64
24.92
59.34
1216.35
8.49
7.93
19.62
5.69
580.18
1124.96
1258.02
10.39
11.74
11.60
15.28
25.82
8.37
466.76
440.22
537.06
15.73
68.36
6.11
59.46
108.32
34.11
22.19
21.32
1.19
77.01
47.81
0.76
1269.13
2202.63
2133.39
18.53
4.44
0.73
1940.59
1217.95
511.23

643.61
160.79
61.05
145.37
2979.43
20.81
19.43
48.08
13.94
1421.14
2755.59
3081.51
25.46
28.75
28.42
37.43
63.25
20.52
1143.33
1078.33
1315.54
38.54
167.46
14.98
145.56
265.35
83.56
54.36
52.22
2.93
188.74
117.11
1.86
2837.87
5395.32
5225.73
45.41
10.88
1.80
2744.40
1722.44
722.98

89.51
65.22
68.65
32.83
351.14
18.77
11.92
32.56
10.51
1973.56
3026.28
981.87
56.38
47.41
88.83
18.88
11.18
12.41
2653.84
3052.77
1820.23
0.00
18.35
0.00
46.34
0.00
25.31
5.15
8.14
1.57
10.08
0.00
0.00
2606.94
2491.14
295.06
10.55
16.07
4.90
1997.42
4258.21
534.02

Here are tables for TGF-beta 1, TGF-beta2, and TGF beta 3, taken at 4, 8, and 12 weeks.
(Table 18) is for the control group and (table 19) is for the Oasis treated group.

Table 18: Showing TGF-beta 1,2 ,&3 in the Control group
TGF-β
Week N Mean S.E. Mean St. dev. Median
TGF-β 1
4 6 0.40
0.40
0.98
0.0
8 6 0.57
0.57
1.41
0.0
12 6 8.92
6.84
16.77
0.0
TGF-β 2

TGF-β 3

4
8

6 0.00
6 0.00

0.00
0.00

0.00
0.00

0.0
0.0

12 6 1.97
4 6 8.04
8 6 6.93

1.97
2.98
3.01

4.83
7.30
7.37

0.0
6.17
4.95

12 6 5.55

1.75

4.30

5.85

Table 19: Showing TGF-beta 1,2,&3 in the study group
TGF-β Week N Mean S.E. Mean St. dev. Median
TGF-β 1 4
6 33.38
28.69
70.29
0.0
8
6 26.29
26.28
64.41
0.0
12 6 20.15
9.45
23.15
14.88
TGF-β 2 4
6 8.13
7.85
19.23
0.0
8
6 0.77
0.77
1.9
0.0
TGF-β 3

12
4
8

6
6
6

8.12
5.69
4.38

5.48
2.99
2.56

13.44
2.99
2.56

1.74
2.52
2.45

12

6 12.83

8.08

8.08

5.45
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Figure 7. In the oasis treated group, VEGF was steadily increasing by week 8 where the healing rate mostly
achieved at this time; however, there were no significant differences between control and experimental
groups at any of the three time points.
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Figure 8. The mean of bFGF in the oasis treated group tripled by week 8 during fibroblast proliferative phase
of wound healing. In the control group, the healing process was hindered by the constant decrease of the
bFGF throughout the research period.
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Figure 9. Showing the IL-1ra was significantly increased in the study group in the week 4, 8, and 12, which
is strongly correlated with the progression of the healing rate that achieved by Oasis-ultra.
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Figure 10. We found that IL-1b was highly expressed in both groups; however, there were no significant
difference between the two groups.
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Figure 11. Showing an increase of PDGF-bb in the oasis treated group compared to the control group in the
period between 4 and 8 week followed by a decrease during week 12, by time wound healed.
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Figure 12. IL6, there are no significant difference between the oasis treated group and the control group at
any time point. Even though the means vary greatly, this is likely due to the immense variance of both groups.
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Figure 13. During the first measurement, on week 4, the levels of IL-8 are very close in the oasis treated and
the control groups. During week 8, IL-8 was increased in the study group compared to the control group. On
week 12 there were no significant difference between the two groups.
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Figure 14. Showing that TNF-α was increased in the control group between weeks 4 and 12, while it was
almost similar between the two groups on week 8. We see that oasis decrease the level of TNF-α specifically
on weeks 4 and 12.
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Figure 15. Showing the inhibitory effect of Oasis on MCP-1: MCP-1 was steadily decreasing between time
points 4, 8, and 12 with a significant difference between weeks 4 and 12 in the same study group. However,
the control group had increased levels of MCP-1 on 4 and 12 weeks, the important stages in wound healing
thus interfering with the recovery process.
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Figure 16. MIP-1 that is responsible for chronic inflammation and delay in wound healing was significantly
increased in the control group compared to the study group during weeks 4 and 12 while it was steadily
decreasing in the study group thus facilitating the healing process.
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Figure 17. Showing the significant difference in TGF-β1 levels during weeks 4 and week 8 compared to the
control group. Higher levels of TGF-β1 are required for wound healing. On the other hand, TGF- β1 was
very minimal expressed in the control group during all time points: 4, 8, and 12.
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Discussion and Conclusion:
Wound healing is a sophisticated process that requires coordinating work of several
different cell types: leukocytes, neutrophils, keratinocytes, fibroblasts, epithelial and
connective tissue cells, inflammatory cells, coagulation factors, growth factors, and
cytokines (Guo & Dipietro, 2010). Each stage of tissue repair involves a highly
orchestrated sequence of events to make the healing process successful (Ghatak et al.,
2015). Thus, wound healing requires precision that is regulated and accomplished by a
complex signaling network of various growth factors, cytokines, and chemokines involved
in a complex integration of signals that coordinate cellular processes (S. Barrientos et al.,
2008b). The aim of this study was to evaluate and assess the key growth factors involved
in wound healing.
In our study, 27 growth factors and cytokines were analyzed using the Bio-Plex
system, and a number of these cytokines were known to be relevant to wound healing
process, for example, vascular endothelial growth factor (VEGF), fibroblast growth factor
(FGF), and transforming growth factor beta-1 (TGF-β1). Each of these growth factors
played a crucial role in the angiogenic process during wound healing. Moreover, FGF and
VEGF are essential factors in the generation of endothelium. Numerous clinical trials that
used collagen-based matrices for treatment of chronic wounds showed great results in
accelerating the healing rate of non-healing wounds (Robson, 1997).
In our present study, we observed that prolonged inflammatory phase in a special
type of chronic wounds, decubitus ulcers or pressure ulcers can alter the important steps of
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wound healing downstream, such as collagen synthesis and angiogenesis. The cytokines
found in high concentrations in chronic wounds (Kasiewicz & Whitehead, 2015) and
involved in the inflammatory phase of wound healing are: IL-1, IL-6, IL-8, TNF-α, MIP1, and MCP-1 (Singer & Clark, 1999). In our research study, we found that IL-1b was
highly expressed in both groups; however, it was expressed higher in the study group
compared to the control group. Vegesna et al. (2005) explained the role of IL-1b to be
enhancing tensile strength of certain defective wounds. We could reach the assumption that
such fluctuation in IL-1b concentration was a natural sequence of events needed to achieve
healing in this type of wounds.
High levels of MCP-1, MIP-1a, and TNF-α have a negative impact on the healing
process thus explaining the rationale of chronicity of pressure ulcers, when these cytokines
are present, as one of the leading causes of inflammation. Pro-inflammatory cytokines,
such as tumor necrosis factor (TNF-α) and interleukin 1b (IL-1b) are the first cells that
show early response during the inflammatory phase (Blackwell & Christman, 1996). Also,
TNF-� is mainly secreted from macrophages and neutrophils during the inflammatory
phase of wound healing (Goel et al., 2010). TNF-α is produced by various cells during the
inflammatory phase thus causing activation of different types of MMPs, and at the same
time suppression of ECM synthesis (Mauviel, Qiu Chen, Dong, Evans, & Uitto, 1993).
Neutrophils are considered to be potent phagocytic cells playing important roles for
keeping wounds clean from any debris. Nevertheless, in the absence of pathogens,
neutrophils are not important in healing wounds (Simpson & Ross, 1972). In their research
paper (1972), Simpson and Ross emphasized that mice with neutropenia, treated with
neutrophils antibodies, showed no significant differences affecting wound closure speed
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compared to the controls. Conversely, most studies have shown that macrophages are the
most predominant cells in the early phase of wound healing that have a significant role in
the healing process (Yates, Hebda, & Wells, 2012). Werner and Grose (2003) mentioned
in their research that macrophages' function was not only restricted on phagocytosis, but
they were also a rich source of different growth factors playing a crucial role in the wound
healing process: transforming growth factor alpha (TGF-α), epidermal growth factor
(EGF), transforming growth factor beta (TGF-β) platelet-derived growth factor (PDGF)
(Penn, Grobbelaar, & Rolfe, 2012). Active macrophages have two phenotypes: M1 and
M2. M1 phenotype is responsible for releasing some of the proinflammatory cytokines,
such as IL-1, IL-6, and TNF-alpha (Koh & DiPietro, 2011); however, M2 phenotype is
regarded as anti-inflammatory and, at the same time, a good source for different growth
factors’ production that are needed for proliferation and wound healing (Martin, Walton,
& Harper, 2009).
In our study, we noticed that certain growth factors and cytokines were linked to
the wound healing process. Some of the important cytokines were: IL-1b, IL-1Ra, IL-6,
IL-8, TNF-alpha, PDGF-bb, bFGF, VEGF, and TGF-β1. Researchers have shed light on
TGF-beta when applied exogenously and how amazing its effect in treating acute wounds
was (Mustoe et al., 1987; Shah, Foreman, & Ferguson, 1995). Also, Pastar et al. (2010)
mentioned in their research that animal wound models showed great healing rates after
recombinant TGF-β application (Pastar et al., 2010). In our study, we intended to
investigate TGF-β1, the growth factor that plays an essential role for cell proliferation and
migration. Although, TGF- β1 total concentration for the three time points, 4, 8, and 12
weeks was low, it shows a great elevation in the study group (Oasis-ultra plus NPWT).
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TGF-β1 was significantly increased in the study group on week 4 and week 8 compared to
the control group; however, overall there is no significant difference between both groups
In the literature, TGF-β1 plays an important role of regulation and stimulation of the
extracellular matrix (ECM) by stimulating fibroblasts to produce collagen. Also, TGF-β1
protects ECM from degradation by inhibiting different proteases (Lafyatis et al., 1990).
TGF-β particularly at the level of epithelial tissues, acts as suppressor to different
cytokines’ activity (Siegel & Massague, 2003). In another highlight study, researchers used
quantitative PCR specifically to test TGF-β receptors obtained from human non-healing
venous ulcers (Pastar et al., 2010). They reached the assumption that chronic venous ulcers
lack TGF-β receptor type II. This result is consistent with Robson (1997) who mentioned
in his research the decreased levels of TGF-beta in chronic wounds (Robson, 1997).
TGF-β1 elicits diverse cellular responses depending on cell type, state of
differentiation, and culture conditions (Barnard, Lyons, & Moses, 1990). In advanced
studies knockout TGF-β1 mice were used. The mice were born without any morphological
defect, but after 2-3 weeks of treatment, they displayed a generalized inflammatory
syndrome, a form of mononuclear cells infiltration to different vital organs, such as heart,
lung, also tissue necrosis, that became lethal (Shull et al., 1992). Also, chronic non-healing
wounds are very strongly associated with reduction in TGF-β signaling (Penn et al., 2012).
Another study found the clear reduction in macrophages, fibronectin, and collagen I & III
deposition in cutaneous rat wounds after adding exogenous neutralizing antibody to TGFβ1 compared to control wounds (Shah et al., 1995). This finding indicates the important
role of TGF-β1 especially during the early wound healing phases.
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To determine the role of the TNF receptor p55 in cutaneous wound repair, Mori et
al., (2002) emphasized the role of TNF-alpha receptors in cutaneous wound healing. He
found that TNF-alpha-receptor-knockout mice were showing great wound healing by
improving angiogenesis and collagen production compared to the wild type (Mori, Kondo,
Ohshima, Ishida, & Mukaida, 2002). Also, among the TNF-receptor-deficient mice group,
the expression of TGF-β1, connective tissue growth factor (CTGF) and VEGF genes were
high (Mori et al., 2002), which explains the increased healing rate through increasing the
proliferation of fibroblasts and increasing the new blood vessels formation via VEGF.
In our research experiments, the study group (Oasis-ultra plus NPWT) did achieve
marked reduction in the level of TNF-α at different time points, 4, 8, and 12 weeks.
Although the reduction was not significant, the clinical healing rate was markedly
improved in the study group as correlated with the reduction in TNF-α and compared to
the control group. Moreover, the TGF-β1 expression level increased in the study group due
to the decrease in the inhibitory effect of TNF-α; at the same time, the level of the TGF-β1
was low in the control group due to high levels of TNF- α and other proinflammatory
cytokines. Therefore, our results were consistent with the findings described by Mori et al.
(2002) in their research. In a number of previous studies, chronic wounds, similar to those
in our target patients, were arrested in the inflammatory phase. Therefore, our focus was
on decreasing the pro-inflammatory cytokines and MMPs concentration (Salazar, Ennis,
& Koh, 2015). While increasing the growth factors that are important for angiogenesis and
fibroblast proliferation and differentiation. That was achieved by applying Oasis-ultra to
stage IV pressure wounds. We need to facilitate the transition of the wound healing process
from the inflammatory phase to the next phase in order to achieve the full healing.
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The patients’ wounds were measured weekly, length x width x depth (cm³). The
closure % calculations were performed using the following formula: % of healing rate =
[(Area on Day 0 - Open Area on Final Day)/Area on Day 0] X 100. Adding Oasis-ultra to
the study group improved the healing rate which reached 87% compared to the control
group with the healing rate of 55%. The median healing rate of the Oasis-ultra treated group
was much higher than the median healing rate of the control group, and the rates between
the groups varied significantly. The Oasis-ultra treated group had a lower variability,
meaning that the healing rate was going on for those six patients at a steadier rate compared
to the control group. Therefore, based on these results, Oasis-ultra was found to be
associated with a more rapid improvement and a higher likelihood of achieving the
complete ulcer closure than the ulcers treated with only NPWT.
Although the inflammatory phase is crucial in the wound healing mechanism, the
proinflammatory cytokines that are produced during this phase will definitely damage
wound tissues leading to ischemia and necrosis, typical events occurring in pressure ulcers
(decubitus ulcers) (Stechmiller et al., 2006).
IL-1ra is a member of the interleukin-1 cytokine family, and it is a natural inhibitor of the
pro-inflammatory effect of IL-1-β. This finding is consistent with Karstoft and Pedersen
(2016), who emphasized in their diabetic research the ability of exercise to increase the
levels of IL-6. The increase of IL-6 lead to diminished TNF-α inflammatory effect and at
the same time stimulated IL-1ra, which is considered to have an anti-inflammatory effect
on IL-1b. IL-1ra is attached to IL-1 receptors; however, no intracellular signaling can
happen (Goto et al., 2015). Previous clinical studies have shown increases in IL-1a and IL1b in chronic inflammatory conditions, for example, periodontitis and gingival tissue from
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patients, compared with healthy subjects (Ishihara et al., 1997; Rawlinson, Dalati, Rahman,
Walsh, & Fairclough, 2000). In a study that was conducted in vivo on a rabbit model of
osteoarthritis (OA), the scientists applied gene therapy and co-expression of interleukin-1
receptor antagonist (IL-1Ra) and transforming growth factor-β1 (TGF-β1) to change the
course of disease. Fluid from the joint was analyzed using ELISA; IL-1ra and TGF-β1 in
the single and double transfection groups showed extraordinary increase. At the same time,
levels of IL-1b and tumor necrosis factor alpha (TNF-α) were measured and showed a
drastic decrease in the study group compared to the control group (Zhang, Zhong, Yu, &
Liu, 2015). We conclude from this experiment that IL-1ra and TGF-β1 have improved
healing of cartilage degeneration and helped the repairing process. From our result, we
noticed high expression of IL-1ra among the Oasis-ultra treated group when compared to
the group treated by NPWT only. Also, during the study that was done on IL-1ra-knockout
mice, the scientists found this group of mice were more likely to contract infection due to
the unopposed effect of IL-1a, which further lead to chronic inflammation, such as
Rheumatoid arthritis (Hirsch, Irikura, Paul, & Hirsh, 1996; Horai et al., 2000; Nicklin,
Hughes, Barton, Ure, & Duff, 2000). In our research, IL-1Ra was significantly increased
in the study group during week 4, week 8, and 12, which meant good prognosis toward the
healing. Also, as we discussed previously that IL-1ra acts as anti-inflammatory cytokine,
which is significantly upregulated by Oasis-ultra treated group compared to the control
group.
Interleukin-6 (IL-6) plays an important role in the wound healing process.
Moreover, it promotes the expression of other cytokines necessary for initiating the wound
healing process, such as, IL-1alpha, IL-1beta, etc. In the in vitro study using corneal
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epithelial cells of rabbits Nakamura and Nishida (1999) mentioned that IL-6 as proinflammatory cytokine promoted cell migration of the rabbit corneal epithelial cells and
wound closure. In another research study that was conducted using IL-6 depleted mice
versus the wild type, it was observed that wounds healed faster in the control group
compared to IL-6 depleted mice, which led us to the conclusion that IL-6 played a role in
wound healing (Z. Q. Lin et al., 2005). In our present study, IL-6, is considered as a
proinflammatory cytokines. Even though the means vary greatly between the oasis-ultra
treated group and the control group, there were no any significant difference between the
two groups at any time point. At the same time, the mean concentration of IL-6 was low
on week 4 in the study group followed by its increase on week 8, which is necessary in
order to stimulate fibroblast and keratinocytes proliferation and migration. Later on, IL-6
decreased again thus leading to the maturation phase that does not need any
proinflammatory cytokines.
The other cytokines that were down regulated by adding oasis-ultra included MIP1a, MIP-1b, and MCP-1 (MCAF). Many research studies have mentioned that in case of
burn wounds, there was a significant increase in the skin proinflammatory cytokines, such
as interleukin 1b, interleukin 6, tumor necrosis factor-α, and the macrophage inflammatory
protein MIP-1b (Rani, Zhang, & Schwacha, 2014). Rani, Zhang, and Schwacha (2014) in
their research study, used special γδ T-cell deficient (δTCR−/−) mice that were exposed to
the third degree burn by using (25% TBSA), and the study revealed that TNF-α, MIP-1a,
and MIP-1b levels doubled or tripled in treated mice compared to the wild type. Similarly,
in our research, these proinflammatory cytokines were highly expressed during stages IV
pressure ulcers in the control group; however, in the study group, where oasis-ultra was
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applied, TNF-α, MIP-1a, and MIP-1b cytokines responsible for delaying healing in these
type of wounds, were inhibited. For example, MIP-1a and MCP-1 were steadily decreased
in the period between week 4 to week 12 in the study group; however, MIP-1a and MCP1 were highly increased during week 4. Even though, these proinflammatory cytokines
decreased on week 8, which could have been caused by the factors like debridement either
mechanical by NPWT following the removal of the sponge that adhered to the wound bed
or using the scalper and scissors, these factors highly increased thus contributing directly
or indirectly to the chronicity of these types of wounds.
Based on the literature and our findings, we reached the assumption that in the
Oasis-ultra treated group, the proinflammatory cytokines were successfully inhibited. The
mediators associated with the wound healing (growth factors and cytokines) can be further
used as a reliable biomarker giving prognosis of the wound healing progress observed in
the clinical settings (Patel et al., 2016).
In conclusion, based on our research results and the data presented, Oasis-ultra
combined with NPWT provides good outcomes for treating stage IV pressure wounds.
Additionally, supplementing Oasis-ultra with NPWT in the study group showed a
successful inhibition of the proinflammatory cytokines while promoting and upregulating
the beneficial growth factors that have a good contribution toward the healing rate.
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